Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-powered risk adjustment, quality management, and HEDIS analytics for health plans and ACOs; raised $60M+. Glendale CA;
Reveleer is a health IT company that provides AI-powered solutions for risk adjustment, quality management, and care gap closure to health plans, ACOs, and provider organizations. Founded in 2014 and headquartered in Glendale, California, Reveleer has raised more than $60 million in growth capital. Its platform combines intelligent document ingestion, natural language processing, and workflow automation to help payers accurately capture risk and close quality gaps at scale, supporting programs like Medicare Advantage, Medicaid Managed Care, and ACA Marketplace.\n\nThe company's core capabilities include automated medical record retrieval, AI-assisted HCC coding review, HEDIS measure tracking, and clinical analytics that surface actionable insights across member populations. Reveleer's platform is designed to serve the full risk adjustment lifecycle from retrospective chart review through prospective care coordination, enabling health plans to improve risk accuracy while simultaneously identifying members who need targeted outreach for quality improvement.\n\nReveleer competes in a market increasingly defined by the financial importance of accurate risk scoring in value-based care contracts. The company has expanded its technology to include an integrated analytics layer that connects risk adjustment and quality data, helping health plans understand the intersection between clinical gaps and revenue impact. Its cloud-native architecture and configurable workflow engine make it adaptable to the specific program requirements of national and regional health plans.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.